State Street
AVTX icon

State Street’s Avalo Therapeutics AVTX Stock Holding History

State Street’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.4M Buy
2,889,287
+2,817,633
+3,932% +$44.5M ﹤0.01% 1802
2026
Q1 		$1.07M Sell
71,654
-7,600
-10% -$119K ﹤0.01% 3473
2025
Q4 		$1.44M Buy
79,254
+33,800
+74% +$570K ﹤0.01% 3434
2025
Q3 		$578K Buy
+45,454
New +$391K ﹤0.01% 3630
2023
Q4 		– Sell
-107
Closed -$3.1K – 4441
2023
Q3 		$3.1K Hold
107
– – ﹤0.01% 4547
2023
Q2 		$9.11K Hold
107
– – ﹤0.01% 4651
2023
Q1 		$44.9K Hold
107
– – ﹤0.01% 4527
2022
Q4 		$131K Hold
107
– – ﹤0.01% 4283
2022
Q3 		$85K Hold
107
– – ﹤0.01% 4515
2022
Q2 		$154K Sell
107
-232
-68% -$310K ﹤0.01% 4324
2022
Q1 		$708K Sell
339
-4
-1% -$10K ﹤0.01% 3916
2021
Q4 		$1.68M Buy
343
+4
+1% +$24K ﹤0.01% 3688
2021
Q3 		$2.13M Buy
339
+12
+4% +$97.3K ﹤0.01% 3594
2021
Q2 		$3.08M Buy
327
+123
+60% +$1.03M ﹤0.01% 3460
2021
Q1 		$1.78M Buy
204
+50
+32% +$472K ﹤0.01% 3481
2020
Q4 		$1.17M Buy
154
+4
+3% +$27.8K ﹤0.01% 3530
2020
Q3 		$983K Buy
150
+13
+9% +$97.7K ﹤0.01% 3444
2020
Q2 		$1.02M Sell
137
-1
-0.7% -$7.26K ﹤0.01% 3413
2020
Q1 		$987K Buy
138
+2
+1% +$21.2K ﹤0.01% 3309
2019
Q4 		$2.12M Buy
136
+17
+14% +$179K ﹤0.01% 3225
2019
Q3 		$1.13M Buy
119
+20
+20% +$223K ﹤0.01% 3371
2019
Q2 		$1.54M Buy
+99
New +$1.5M ﹤0.01% 3331

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's AVTX Position: Q2 2026 in Review

State Street increased its Avalo Therapeutics (AVTX) stake by 3,932% in Q2 2026, buying an estimated $44.5M and bringing the position to 2,889,287 shares worth $53.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

State Street first reported a position in AVTX in Q2 2019 and has held it in 22 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • State Street held 2,889,287 shares of Avalo Therapeutics worth $53.4M as of Q2 2026.
  • State Street bought 2,817,633 Avalo Therapeutics shares in Q2 2026, an estimated $44.5M.
  • Avalo Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1802 holding.
  • State Street first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.